This is a working overview of regulatory status, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-07. Anything still debated is marked as such rather than presented as settled.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
== Further reading == "Bernie Sanders Explains... Why Americans Are Furious at the Democrats: The Nation Interview [by John Nichols]", The Nation, vol. 321, no. 4 (November 2025), pp. 30–34. "[T]he [Democratic] party is saying, '[W]e can't support [Zohran Mamdani, running for New York City mayor] because he is saying what 75 percent of Democrats say about Israel: No more money for Netanyahu.' [p. 32.] [T]he money people decide who the candidates are... [p. 33.] A few years ago ... a poll [showed that] [a]lmost 60 percent of the people said [they] were better off 50 years ago. [p. 34.]" Chiasson, Dan (2026). Bernie for Burlington: The Rise of the People's Politician. New York: Knopf. ISBN 978-0-59331-749-5. Rall, Ted (2016). Bernie. New York: Hollowbrook Publishing. ISBN 978-1-60980-698-9. Rice, Tom W. (1985). "Who Votes for a Socialist Mayor?: The Case of Burlington, Vermont". Polity. 17 (4): 795–806. doi:10.2307/3234575. ISSN 0032-3497. JSTOR 3234575. OCLC 5546248357. S2CID 153889856. Rosenfeld, Steven (1992). Making History in Vermont: The Election of a Socialist to Congress. Wakefield, NH: Hollowbrook Publishing. ISBN 978-0-89341-698-0. LCCN 91034055. OCLC 24468446. OL 1553980M. Soifer, Steven (1991). The Socialist Mayor: Bernard Sanders in Burlington, Vermont. Westport, CN: Praeger. ISBN 978-0-89789-219-3. LCCN 90048954. OCLC 22491683. OL 1887682M.
=== Mechanism of action === Mebeverine is an antispasmodic but its mechanism of action is not known; it appears to work directly on smooth muscle within the gastrointestinal tract and may have an anaesthetic effect, may affect calcium channels, and may affect muscarinic receptors.
The confirmation test in most laboratories (and all SAMHSA certified labs) is performed using mass spectrometry, and is precise but expensive. False positive samples from the screening test will almost always be negative on the confirmation test. Samples testing positive during both screening and confirmation tests are reported as positive to the entity that ordered the test. Most laboratories save positive samples for some period of months or years in the event of a disputed result or lawsuit. For workplace drug testing, a positive result is generally not confirmed without a review by a Medical Review Officer who will normally interview the subject of the drug test.
Sources: en.wikipedia.org
The gastric juice also contains digestive enzymes produced by other cells in the gastric glands – gastric chief cells. Gastric chief cells secrete an inactivated pepsinogen. Once in the stomach lumen gastric acid activates the proenzyme to pepsin.
== Pumps used in high-pressure chromatography == Pumps used in high-pressure chromatography such as HPLC and ion chromatography are much like small piston metering pumps. For wear resistance and chemical resistance to solvents, etc., typically the pistons are made of artificial sapphire and the ball check valves have ruby balls and sapphire seats. To produce good chromatograms, it is desirable to have a pumping flow rate as constant as possible. Either a single piston pump with a quick refill is used or a double pump head with coordinated piston strokes is used to provide as constant a pumping rate as possible.
== Shelf life == The shelf life of rations depends on the type and purpose, including how long the ration is intended to be used or kept until logistics and steady food supplies can reach the front lines. Per NATO standardization, the shelf life of a field ration from the time of delivery must be at least 24 months at a storage temperature of 25 °C; individual rations are designed to be used for a period of 30 days, after which fresh food should be given and medical screening should be conducted for nutritional deficiencies.
==== iLet Bionic Pancreas ==== The iLet Bionic Pancreas system, developed by Beta Bionics, is an automated insulin delivery system comprising the iLet ACE Pump, the iLet Dosing Decision Software, and a compatible continuous glucose monitor — either the Dexcom G6/G7 or the FreeStyle Libre 3 Plus sensor. The system is designed to automate insulin dosing with minimal user input, relying solely on the user’s body weight for initialization. It utilizes three algorithms to manage insulin delivery: a basal insulin controller, which adjusts basal rates every five minutes based on current glucose values, glucose trends, and historical CGM data; a bolus correction controller, which incorporates insulin on board in addition to these factors to calculate correction doses; and a meal announcement controller, which determines bolus doses according to the user’s estimation of meal size. The system does not require user-programmed basal rates, insulin-to-carbohydrate ratios, or correction factors. It supports three glucose targets—110, 120, or 130 mg/dL—and is approved for use in individuals aged six years and older with type 1 diabetes.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.